BridgeMD
Comparison of treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery.
EU CTIS ID: 2024-517572-38-00
What this study is testing
Comparison of treatment with preservative-free eye drops versus preserved eye drops after cataract surgery
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- patients diagnosted with age-related cataract
- Age 60 years or above
You likely can't join if
- Pre-existing dry eye disease according to the criteria's of the TFOS DEXS II report
- pseudoexfoliation syndrome
- functionally monocular patient
- any use of eye drops during at least 3 months before surgery with exception of artificial tears
- previous ocular injury, surgery or laser treatment, uveitis
- presence of any macular disease possibly impacting visual acuity
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.